Condition
Dyslipidemia Clinical Trials
Studies of dyslipidemia, matched by condition name and medical subject headings. Start with those open to enrolment.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 356Heterozygous Familial Hypercholesterolemia (HeFH)
EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C)
A phase 1/2, two-part trial consisting of an open label dose-escalation part and a randomized, double blind, placebo-controlled part to investigate safety, tolerability, pharmacokinetics, and efficacy with EDIT-401 gene editing…
- Trial name
- NCT07894887
- Testing
- Drug: EDIT-401
- Where
- 2 sites in Australia
- Volunteers
- 56 people
- Sponsor
- Editas Medicine, Inc.
Hyperlipidemia
A Study to Evaluate COR-1004 in Adult Volunteers.
This research study is being done to see if a new, injectable drug called COR-1004 is safe for people to take. It will also help doctors find the right dose of the drug.
- Trial name
- NCT07229118
- Testing
- COR-1004
- Where
- 2 sites in New Zealand
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Corsera Health
Lipid Metabolism Disorders
Plasma Lipids-Dependent Vitamin E Metabolism During Dynamic Hyperlipidemia
Background: Obesity is known to lead to diseases such as diabetes and high cholesterol (or fats) in the blood (hyperlipidemia). But no one knows why.
- Trial name
- NCT07715890
- Testing
- High fat liquid shake
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hypercholesterolemia, Atherosclerosis
Causes and Natural History of Dyslipidemias
This study will evaluate people with dyslipidemias - disorders that affect the fat content in the blood. Fats, or lipids, such as cholesterol and triglycerides, are carried in the blood in particles called lipoproteins.
- Trial name
- NCT00353782
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Homozygous Familial Hypercholesterolemia
Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia
This study will evaluate the efficacy and safety of zodasiran subcutaneous (sc) injection in participants 12 to <18 years of age with genetically or clinically diagnosed homozygous familial hypercholesterolemia (HoFH) and…
- Trial name
- SPRUCE (NCT07473843)
- Testing
- Zodasiran
- Where
- 3 sites in United States, Denmark and 1 more
- Volunteers
- 10 people
- Sponsor
- Arrowhead Pharmaceuticals
Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization.
- Trial name
- V-INTERVENTION (NCT06909565)
- Testing
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Where
- 147 sites in United States
- Volunteers
- 6,000 people
- Sponsor
- Duke University
Antiphospholipid (aPL)-Positive, Rheumatic Arthritis
MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)
The primary objective of this multicenter observational registry is to characterize the clinical, epidemiological, and biological profiles of individuals of Middle Eastern, North African, and Levantine ancestry, including…
- Conditions
- Antiphospholipid (aPL)-Positive, Rheumatic Arthritis, Celiac Disease, Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- MERIT (NCT07892651)
- Where
- Jordan
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Axiom Bioregistry
Hypercholesterolemia, Hypertriglyceridemia
Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia.
- Conditions
- Hypercholesterolemia, Hypertriglyceridemia, Refractory Hyperlipidemia
- Trial name
- NCT06451770
- Testing
- VERVE-201
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 132 people
- Sponsor
- Verve Therapeutics, Inc.
Hyperlipidemia, Hypercholesterolemia
A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)
Researchers are looking for new ways to treat high cholesterol. Cholesterol is a type of fat in the blood. Enlicitide (also known as enlicitide decanoate or MK-0616), the study medicine, is in a class of medicines designed to…
- Trial name
- NCT07821944
- Testing
- Enlicitide Decanoate
- Where
- India
- Volunteers
- 150 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Myocardial Infarction, Dyslipidemias
Ezetimibe Utilization Early After Acute Myocardial Infarction, "EzAMI Trial"
Rationale: Patients with acute coronary syndromes are at an increased risk for recurrent adverse coronary events, particularly during the early period following their initial presentation.
- Trial name
- EzAMI (NCT04701242)
- Testing
- Ezetimibe 10mg
- Where
- Egypt
- Volunteers
- 500 people
- Sponsor
- Cairo University
Completed, with results posted
All 554Obesity, Hypertension
HealthMatters@24/7 eLearning for People Supporting Adults With Intellectual and Developmental Disabilities
The barriers faced by people with intellectual and developmental disabilities (IDD) begin in their mid to late 20s and often mirror the experiences of older adults (50+) living in the U.S.
- Conditions
- Obesity, Hypertension, Hypercholesterolemia, Hyperglycemia
- Trial name
- HM@24/7 (NCT03206164)
- Testing
- Asynchronous, eLearning Intervention
- Where
- United States
- Volunteers
- 274 people, healthy volunteers welcome
- Sponsor
- University of Illinois at Chicago
Lipid Disorder
EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders)
The EMERALD intervention involves 1) ordering an Emergency Department (ED) lipid panel, 2) calculating 10-year Atherosclerotic cardiovascular disease (ASCVD) risk using the Pooled Cohort Equations, 3) prescribing a moderate- or…
- Trial name
- EMERALD (NCT05742841)
- Testing
- moderate- or high-intensity statin/ rosuvastatin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Wake Forest University Health Sciences
Hypercholesterolaemia
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020)
The primary objective of the study is to compare the plasma pharmacokinetics (PK) of enlicitide decanoate following a single 20 mg dose in participants on a background of statin therapy with varying degrees of renal impairment…
- Trial name
- NCT05934292
- Testing
- Enlicitide Decanoate
- Where
- 5 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hypercholesterolemia, Familial Hypercholesterolemia
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids
The goal of this study is to evaluate the efficacy, safety, and tolerability of enlicitide decanoate in adult participants with hypercholesterolemia.
- Trial name
- NCT05952856
- Testing
- Enlicitide Decanoate
- Where
- 168 sites in United States, Argentina and 12 more
- Volunteers
- 2,912 people
- Sponsor
- Merck Sharp & Dohme LLC
Cardiovascular Diseases, Type 2 Diabetes Mellitus in Obese
Implementation of a Peer Leader-facilitated Dyadic Intervention
This Pilot Study Large Application builds upon the results of our prior work to 1) Implement and pilot test a peer leader-facilitated 12-week dyadic intervention (Community Health among Asian Indian immigrants (CHAI) Dyad study)…
- Conditions
- Cardiovascular Diseases, Type 2 Diabetes Mellitus in Obese, Hyperlipidemias
- Trial name
- NCT06643806
- Testing
- CHAI dyad study
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey